Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing

Journal of Clinical Microbiology

Volumn 50, Issue 6, 2012, Pages 2026-2033

  Engström, Anna ^a,b   Morcillo, Nora ^c   Imperiale, Belen ^c   Hoffner, Sven E ^a,b   Juréen, Pontus ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c Hospital Zonal de Agudos y Cronicos Dr Antonio A Cetrangolo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; ISONIAZID; KANAMYCIN; OFLOXACIN; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIUM ISOLATE; CONTROLLED STUDY; EIS GENE; EMBB GENE; GENE LOCUS; GYRA GENE; INHA GENE; INTERMETHOD COMPARISON; KATG GENE; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MULTILOCUS SEQUENCE TYPING; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROMOTER REGION; PYROSEQUENCING; RPOB GENE; RRS GENE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TURNAROUND TIME;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PROMOTER REGIONS, GENETIC; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84862099674     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.06664-11     Document Type: Article

References (68)

1. Alangaden GJ, et al. 1998. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:1295-1297. (Pubitemid 28227943)
2. Arnold C, et al. 2005. Single-nucleotide polymorphism-based differentiation and drug resistance detection in Mycobacterium tuberculosis from isolates or directly from sputum. Clin. Microbiol. Infect. 11:122-130. (Pubitemid 40253816)
3. Banerjee A, et al. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230. (Pubitemid 24067929)
4. Bravo LT, et al. 2009. Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones. J. Clin. Microbiol. 47:3985-3990.
5. Campbell EA, et al. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901-912. (Pubitemid 32289282)
6. Campbell PJ, et al. 2011. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:2032-2041.
7. Camus JC, Pryor MJ, Medigue C, Cole ST. 2002. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 148:2967-2973. (Pubitemid 35243696)
8. Centers for Disease Control. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55:301-305.
9. Chakravorty S, et al. 2011. Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay. J. Clin. Microbiol. 49:932-940.
10. da Silva PE, Von Groll A, Martin A, Palomino JC. 2011. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol. Med. Microbiol. 63:1-9.
11. Engström A, Perskvist N, Werngren J, Hoffner SE, Jureen P. 2011. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 66:1247-1254.
12. Griffith ME, Bodily HL. 1992. Stability of antimycobacterial drugs in susceptibility testing. Antimicrob. Agents Chemother. 36:2398-2402.
13. Hall TA. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. 41:95-98.
14. Heep M, et al. 2001. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 39:107-110. (Pubitemid 32059577)
15. Heifets LB, Iseman MD, Lindholm-Levy PJ. 1986. Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 30:927-932. (Pubitemid 17209151)
16. Helb D, et al. 2010. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol. 48:229-237.
17. Hillemann D, Rusch-Gerdes S, Richter E. 2007. Evaluation of the Geno-Type MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 45:2635-2640. (Pubitemid 47295497)
18. Hillemann D, Rusch-Gerdes S, Richter E. 2009. Feasibility of the Geno-Type MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 47:1767-1772.
19. Hofmann-Thiel S, et al. 2009. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur. Respir. J. 33:368-374.
20. Huang WL, Chi TL, Wu MH, Jou R. 2011. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 49:2502-2508.
21. Johansen SK, Maus CE, Plikaytis BB, Douthwaite S. 2006. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2=-Omethylations in 16S and 23S rRNAs. Mol. Cell 23:173-182. (Pubitemid 44081881)
22. Johnsson K, Schultz PG. 1994. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J. Am. Chem. Soc. 116:7425-7426. (Pubitemid 24274243)
23. Jureen P, et al. 2006. Rapid detection of rifampin resistance in Mycobacterium tuberculosis by pyrosequencing technology. J. Clin. Microbiol. 44:1925-1929. (Pubitemid 43902137)
24. Jureen P, Werngren J, Hoffner SE. 2004. Evaluation of the line probe assay (LiPA) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb.) 84:311-316. (Pubitemid 38858117)
25. Kiepiela P, Bishop KS, Smith AN, Roux L, York DF. 2000. Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tuber. Lung Dis. 80:47-56. (Pubitemid 30179493)
26. Larsen MH, et al. 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol. Microbiol. 46:453-466. (Pubitemid 35340956)
27. Madison B, et al. 2002. Multicenter evaluation of ethambutol susceptibility testing of mycobacterium tuberculosis by agar proportion and radiometric methods. J. Clin. Microbiol. 40:3976-3979. (Pubitemid 35285776)
28. Maus CE, Plikaytis BB, Shinnick TM. 2005. Molecular analysis of crossresistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:3192-3197. (Pubitemid 41060560)
29. Maus CE, Plikaytis BB, Shinnick TM. 2005. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:571-577. (Pubitemid 40175664)
30. Miller LP, Crawford JT, Shinnick TM. 1994. The rpoB gene of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38:805-811. (Pubitemid 24114022)
31. Moazed D, Noller HF. 1987. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 327:389-394. (Pubitemid 17075811)
32. Musser JM. 1995. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin. Microbiol. Rev. 8:496-514.
33. Nyrén P. 2007. The history of pyrosequencing. Methods Mol. Biol. 373:1-14.
34. Piton J, et al. 2010. Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One 5:e12245.
35. Plinke C, et al. 2009. Tuberculosis ethambutol resistance: concordance between phenotypic and genotypic test results. Tuberculosis (Edinb.) 89:448-452.
36. Plinke C, Rusch-Gerdes S, Niemann S. 2006. Significance of mutations in embB codon 306 for prediction of ethambutol resistance in clinical Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 50:1900-1902.
37. Plinke C, Walter K, Aly S, Ehlers S, Niemann S. 2011. Mycobacterium tuberculosis embB codon 306 mutations confer moderately increased resistance to ethambutol in vitro and in vivo. Antimicrob. Agents Chemother. 55:2891-2896.
38. Prammananan T, et al. 1998. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J. Infect. Dis. 177:1573-1581. (Pubitemid 28243581)
39. Quémard A, et al. 1995. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34:8235-8241.
40. Ramaswamy S, Musser JM. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 79:3-29. (Pubitemid 29050434)
41. Ramaswamy SV, et al. 2000. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:326-336. (Pubitemid 30060727)
42. Ronaghi M, Uhlen M, Nyren P. 1998. A sequencing method based on real-time pyrophosphate. Science 281:363, 365.
43. Rozwarski DA, Grant GA, Barton DH, Jacobs WR, Jr, Sacchettini JC. 1998. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279:98-102. (Pubitemid 28079164)
44. Safi H, Sayers B, Hazbon MH, Alland D. 2008. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob. Agents Chemother. 52:2027-2034. (Pubitemid 351758539)
45. Sandegren L, et al. 2011. Genomic stability over 9 years of an isoniazid resistant Mycobacterium tuberculosis outbreak strain in Sweden. PLoS One 6:e16647.
46. Sandgren A, et al. 2009. Tuberculosis drug resistance mutation database. PLoS Med. 6:e2.
47. Schön T, et al. 2009. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J. Antimicrob. Chemother. 64:786-793.
48. Scorpio A, Zhang Y. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667. (Pubitemid 26191953)
49. Siu GK, et al. 2011. Mutations outside the rifampicin resistancedetermining region associated with rifampicin resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 66:730-733.
50. Sreevatsan S, et al. 1997. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc. Natl. Acad. Sci. U. S. A. 94:9869-9874. (Pubitemid 27408157)
51. Sreevatsan S, et al. 1997. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob. Agents Chemother. 41:1677-1681. (Pubitemid 27339866)
52. Starks AM, Gumusboga A, Plikaytis BB, Shinnick TM, Posey JE. 2009. Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 53:1061-1066.
53. Sun Z, et al. 2008. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int. J. Antimicrob. Agents 31:115-121.
54. Suzuki Y, et al. 1998. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J. Clin. Microbiol. 36:1220-1225. (Pubitemid 28208002)
55. Takayama K, Kilburn JO. 1989. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 33:1493-1499. (Pubitemid 19228001)
56. Takiff HE, et al. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780. (Pubitemid 24114017)
57. Taniguchi H, et al. 1997. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system. J. Bacteriol. 179:4795-4801. (Pubitemid 27339725)
58. Telenti A, et al. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647-650. (Pubitemid 23083244)
59. Telenti A, et al. 1997. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat. Med. 3:567-570. (Pubitemid 27198658)
60. Vilchèze C, and Jacobs WR, Jr. 2007. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu. Rev. Microbiol. 61:35-50. (Pubitemid 350058198)
61. Wang JC. 1985. DNA topoisomerases. Annu. Rev. Biochem. 54:665-697. (Pubitemid 15073661)
62. World Health Organization. 2009. Guidelines for surveillance of drug resistance in tuberculosis. WHO/HTM/TB/2009.422. World Health Organization, Geneva, Switzerland.
63. World Health Organization and Stop Partnership TB. 2010. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis. World Health Organization, Geneva, Switzerland.
64. World Health Organization. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response, WHO/HTM/TB/2010, 3rd ed. World Health Organization, Geneva, Switzerland.
65. Xu C, Kreiswirth BN, Sreevatsan S, Musser JM, Drlica K. 1996. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J. Infect. Dis. 174:1127-1130. (Pubitemid 26357484)
66. Zaunbrecher MA, Sikes RD, Jr, Metchock B, Shinnick TM, Posey JE. 2009. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 106:20004-20009.
67. Zhang Y, Heym B, Allen B, Young D, Cole S. 1992. The catalaseperoxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358:591-593.
68. Zhang Y, Yew WW. 2009. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13:1320-1330.